Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00958698UNKNOWNNAINTERVENTIONAL

Summary

Key Facts

Lead Sponsor

Gynecologic Oncology Group

Enrollment

485

Start Date

2010-01-19

Completion Date

2017-01-08

Study Type

INTERVENTIONAL

Official Title

NURSE-DELIVERED WRITE SYMPTOMS vs. SELF-DIRECTED WRITE SYMPTOMS vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Interventions

Communication InterventionEducational InterventionInternet-Based InterventionPsychosocial Assessment and CareQuality-of-Life AssessmentQuestionnaire Administration

Conditions

Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaPsychological Impact of CancerRecurrent Ovarian Carcinoma

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* Diagnosis of ovarian, fallopian tube, or primary peritoneal cancer that has recurred or persisted following primary therapy

  * Active disease or current treatment are not required
* Must be experiencing ? 3 symptoms associated with ovarian cancer or cancer treatment, including, but not limited to, any of the following:

  * Abdominal bloating or cramping
  * Nausea, vomiting, or diarrhea
  * Constipation
  * Anorexia
  * Anxiety
  * Depression
  * Dizziness
  * Drowsiness
  * Dry mouth
  * Fatigue
  * Headaches
  * Hair loss
  * Hot flashes
  * Memory concerns
  * Mood swings
  * Mouth sores
  * Pain
  * Peripheral neuropathies
  * Sexuality concerns
  * Sleep disturbances
  * Shortness of breath
  * Skin rash or palmar-plantar erythrodysesthesia
  * Urinary problems
  * Weight gain or loss
* GOG performance status 0-2
* Able to read and write English
* Access to computer and the Internet required
* Concurrent treatment on other clinical trials allowed

Outcome Measures

Primary Outcomes

Symptom severity, symptom-related distress, consequences, and control of symptoms as measured by the Symptom Representation Questionnaire

Time frame: Baseline and at 4, 8, and 12 weeks

Secondary Outcomes

Health-related quality of life as measured by the FACT-O

Time frame: Baseline and at 4, 8, and 12 weeks, and every 4 weeks for 1 year

Depressive symptoms as measured by the CES-D short form

Time frame: Baseline and at 4, 8, and 12 weeks, and every 4 weeks for 1 year

Communication with health care providers and use of self-care strategies assessed by investigator-developed survey

Time frame: Baseline and at 4, 8, and 12 weeks

Implementation and perceived effectiveness of new symptom management strategies assessed by questionnaire

Time frame: Baseline and at 4, 8, and 12 weeks

Barriers to symptom management as measured by the Symptom Management Barriers Questionnaire

Time frame: Baseline and at 4, 8, and 12 weeks

Locations

Gynecologic Oncology Group of Arizona, Phoenix, United States

Cedars Sinai Medical Center, Los Angeles, United States

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, United States

Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, United States

University of Colorado Hospital, Aurora, United States

Hartford Hospital, Hartford, United States

The Hospital of Central Connecticut, New Britain, United States

Queen's Medical Center, Honolulu, United States

University of Hawaii Cancer Center, Honolulu, United States

Kapiolani Medical Center for Women and Children, Honolulu, United States

Decatur Memorial Hospital, Decatur, United States

Memorial Medical Center, Springfield, United States

Carle Cancer Center, Urbana, United States

Elkhart Clinic, Elkhart, United States

Michiana Hematology Oncology PC-Elkhart, Elkhart, United States

Elkhart General Hospital, Elkhart, United States

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, United States

Community Howard Regional Health, Kokomo, United States

IU Health La Porte Hospital, La Porte, United States

Michiana Hematology Oncology PC-Mishawaka, Mishawaka, United States

Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, United States

Michiana Hematology Oncology PC-Plymouth, Plymouth, United States

Memorial Hospital of South Bend, South Bend, United States

Michiana Hematology Oncology PC-South Bend, South Bend, United States

South Bend Clinic, South Bend, United States

Northern Indiana Cancer Research Consortium, South Bend, United States

Michiana Hematology Oncology PC-Westville, Westville, United States

Medical Oncology and Hematology Associates-West Des Moines, Clive, United States

Mercy Cancer Center-West Lakes, Clive, United States

Iowa Methodist Medical Center, Des Moines, United States

Iowa-Wide Oncology Research Coalition NCORP, Des Moines, United States

Medical Oncology and Hematology Associates-Des Moines, Des Moines, United States

Medical Oncology and Hematology Associates-Laurel, Des Moines, United States

Mercy Medical Center - Des Moines, Des Moines, United States

Iowa Lutheran Hospital, Des Moines, United States

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, United States

Methodist West Hospital, West Des Moines, United States

Mercy Medical Center-West Lakes, West Des Moines, United States

Providence Medical Center, Kansas City, United States

Menorah Medical Center, Overland Park, United States

Saint Luke's South Hospital, Overland Park, United States

Kansas City NCI Community Oncology Research Program, Prairie Village, United States

Shawnee Mission Medical Center-KCCC, Shawnee Mission, United States

CHRISTUS Highland Medical Center, Shreveport, United States

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, United States

Walter Reed National Military Medical Center, Bethesda, United States

Massachusetts General Hospital Cancer Center, Boston, United States

Beth Israel Deaconess Medical Center, Boston, United States

University of Massachusetts Memorial Health Care, Worcester, United States

University of Massachusetts Medical School, Worcester, United States

Wayne State University/Karmanos Cancer Institute, Detroit, United States

Green Bay Oncology - Escanaba, Escanaba, United States

Spectrum Health at Butterworth Campus, Grand Rapids, United States

Green Bay Oncology - Iron Mountain, Iron Mountain, United States

Bronson Methodist Hospital, Kalamazoo, United States

West Michigan Cancer Center, Kalamazoo, United States

Borgess Medical Center, Kalamazoo, United States

Lakeland Hospital Niles, Niles, United States

William Beaumont Hospital-Royal Oak, Royal Oak, United States

Lakeland Medical Center Saint Joseph, Saint Joseph, United States

Marie Yeager Cancer Center, Saint Joseph, United States

Fairview Ridges Hospital, Burnsville, United States

Mercy Hospital, Coon Rapids, United States

Fairview-Southdale Hospital, Edina, United States

Unity Hospital, Fridley, United States

Hutchinson Area Health Care, Hutchinson, United States

Minnesota Oncology Hematology PA-Maplewood, Maplewood, United States

Saint John's Hospital - Healtheast, Maplewood, United States

Abbott-Northwestern Hospital, Minneapolis, United States

Hennepin County Medical Center, Minneapolis, United States

University of Minnesota/Masonic Cancer Center, Minneapolis, United States

New Ulm Medical Center, New Ulm, United States

North Memorial Medical Health Center, Robbinsdale, United States

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, United States

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, United States

Regions Hospital, Saint Paul, United States

United Hospital, Saint Paul, United States

Saint Francis Regional Medical Center, Shakopee, United States

Lakeview Hospital, Stillwater, United States

Ridgeview Medical Center, Waconia, United States

Rice Memorial Hospital, Willmar, United States

Minnesota Oncology Hematology PA-Woodbury, Woodbury, United States

Truman Medical Center, Kansas City, United States

Saint Luke's Hospital of Kansas City, Kansas City, United States

Saint Joseph Health Center, Kansas City, United States

North Kansas City Hospital, Kansas City, United States

Heartland Hematology and Oncology Associates Incorporated, Kansas City, United States

Research Medical Center, Kansas City, United States

Saint Luke's East - Lee's Summit, Lee's Summit, United States

Liberty Radiation Oncology Center, Liberty, United States

Heartland Regional Medical Center, Saint Joseph, United States

Saint Joseph Oncology Inc, Saint Joseph, United States

Mercy Hospital Springfield, Springfield, United States

CoxHealth South Hospital, Springfield, United States

Washington University School of Medicine, St Louis, United States

Billings Clinic Cancer Center, Billings, United States

Nebraska Methodist Hospital, Omaha, United States

University of Nebraska Medical Center, Omaha, United States

University of New Mexico Cancer Center, Albuquerque, United States

Southwest Gynecologic Oncology Associates Inc, Albuquerque, United States

Memorial Medical Center - Las Cruces, Las Cruces, United States

Island Gynecologic Oncology, Brightwaters, United States

Summa Akron City Hospital/Cooper Cancer Center, Akron, United States

Cleveland Clinic Akron General, Akron, United States

Case Western Reserve University, Cleveland, United States

MetroHealth Medical Center, Cleveland, United States

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, United States

Cleveland Clinic Foundation, Cleveland, United States

Ohio State University Comprehensive Cancer Center, Columbus, United States

Riverside Methodist Hospital, Columbus, United States

Miami Valley Hospital, Dayton, United States

Hillcrest Hospital Cancer Center, Mayfield Heights, United States

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, United States

University of Oklahoma Health Sciences Center, Oklahoma City, United States

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, United States

Abington Memorial Hospital, Abington, United States

Lehigh Valley Hospital-Cedar Crest, Allentown, United States

Bryn Mawr Hospital, Bryn Mawr, United States

Paoli Memorial Hospital, Paoli, United States

UPMC-Magee Womens Hospital, Pittsburgh, United States

West Penn Hospital, Pittsburgh, United States

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, United States

Lankenau Medical Center, Wynnewood, United States

Main Line Health NCORP, Wynnewood, United States

Women and Infants Hospital, Providence, United States

Medical University of South Carolina, Charleston, United States

The Methodist Hospital System, Houston, United States

Virginia Commonwealth University/Massey Cancer Center, Richmond, United States

Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, United States

Green Bay Oncology at Saint Vincent Hospital, Green Bay, United States

Saint Vincent Hospital Cancer Center Green Bay, Green Bay, United States

Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, United States

Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, United States

University of Wisconsin Hospital and Clinics, Madison, United States

Holy Family Memorial Hospital, Manitowoc, United States

Bay Area Medical Center, Marinette, United States

Marshfield Medical Center-Marshfield, Marshfield, United States

Aurora Saint Luke's Medical Center, Milwaukee, United States

Marshfield Clinic-Minocqua Center, Minocqua, United States

Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, United States

Marshfield Medical Center-Rice Lake, Rice Lake, United States

Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, United States

Aurora West Allis Medical Center, West Allis, United States

Marshfield Clinic - Weston Center, Weston, United States

Linked Papers

2022-02-07

Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)

PURPOSE GOG-259 was a 3-arm randomized controlled trial of two web-based symptom management interventions for patients with recurrent ovarian cancer. Primary aims were to compare the efficacy of the nurse-guided (Nurse-WRITE) and self-directed (SD-WRITE) interventions to Enhanced Usual Care (EUC) in improving symptoms (burden and controllability) and quality of life (QOL). METHODS Patients with recurrent or persistent ovarian, fallopian, or primary peritoneal cancer with 3+ symptoms were eligible for the study. Participants completed baseline (BL) surveys (symptom burden and controllability and QOL) before random assignment. WRITE interventions lasted 8 weeks to develop symptom management plans for three target symptoms. All women received EUC: monthly online symptom assessment with provider reports; online resources; and every 2-week e-mails. Outcomes were evaluated at 8 and 12 weeks after BL. Repeated-measures modeling with linear contrasts evaluated group by time effects on symptom burden, controllability, and QOL, controlling for key covariates. RESULTS Participants (N = 497) reported mean age of 59.3 ± 9.2 years. At BL, 84% were receiving chemotherapy and reported a mean of 14.2 ± 4.9 concurrent symptoms, most commonly fatigue, constipation, and peripheral neuropathy. Symptom burden and QOL improved significantly over time ( P < .001) for all three groups. A group by time interaction ( P < .001) for symptom controllability was noted whereby both WRITE intervention groups had similar improvements from BL to 8 and 12 weeks, whereas EUC did not improve over time. CONCLUSION Both WRITE Intervention groups showed significantly greater improvements in symptom controllability from BL to 8 and BL to 12 weeks compared with EUC. There were no significant differences between Nurse-WRITE and SD-WRITE. SD-WRITE has potential as a scalable intervention for a future implementation study.